Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small cell lung cancer receiving 1 st -line chemotherapy: a Phase 1b/randomized Phase 2 trial
AbstractBackground. Chemotherapy-induced damage of hematopoietic stem and progenitor cells (HSPC) causes multi-lineage myelosuppression. Trilaciclib is an intr
CDK4/6 inhibitor to prevent ... neutropenia (!!!!) induced by chemo. A randomized trial. I m lost with this drug family: it induces neutropenia as single agent and prevents neutropenia when given with chemo 🤔
Rates of grade 3/4 neutropenia: ~65% w/ CDK4/6i [MONALEESA2] ~20% w/ platinum/etop [IMpower133] Combine CDK4/6i 'trilaciclib' with platinum/etop for small cell #lcsm: And ↓ neutropenia, neutropenic fever, G-CSF use. What? So cool, and puzzling!
Stephen V Liu
#OncoAlert Use of trilaciclib (CDK4/6 inhibitor) reduces heme toxicity from chemo in #SCLC. Drug induces G1 arrest in cells with intact Rb. Protects hematopoietic stem cells from cytotoxic effects of chemo without protecting #SCLC cells. #LCSM
Innovative approach to protect hematopoiesis from chemotherapy induced toxicity. Applicability in hematologic cancer originating from those cells however yet to be determined.